Tiffany Wilson

Tiffany has spent more than 15 years bringing innovative medical technology from benchtop to bedside. She joined GCMI in 2011 to lead its startup phase, establishing overall strategic vision, building strategic relationships and bringing together key stakeholders of the medical device ecosystem. Her strong background in medical devices, commitment to fostering innovation and understanding of business strategies have propelled her into a leadership role in the Southeast and brought her into the national spotlight. Wilson joined GCMI from Scientific Intake, where she served as the Vice President of Business Development and Strategy, evaluating marketing and distribution opportunities and driving product development projects for the global obesity market. Prior to Scientific Intake, she was Vice President of Corporate Strategy and Finance at ACell, Inc., a regenerative medicine and tissue engineering company based in Columbia, Maryland. At ACell, she led a broad range of initiatives including corporate finance, investor relations, strategic and operational planning, business development, regulatory, and reimbursement. Tiffany serves as Past-President of the Board of the Southeast Medical Device Association (SEMDA), Founding Member of Medtech Women @ SEMDA, Chair of the T3 Labs Advisory Board, and the Georgia Bio Board of Directors. She is a Member of the National Advisory Council on Innovation and Entrepreneurship (NACIE) at the U.S. Department of Commerce. She led the Sponsorship Committee of the 2013 SEMDA Conference and has served as the Co-Chair of the Medical Device Subcommittee of the Metro Atlanta Chamber Bioscience Leadership Council. In 2015 Tiffany received the prestigious Georgia Bio Community Award and in 2017 was presented with the Industry Growth Award, the highest honor bestowed each year by Georgia Bio.  She was recently recognized by Inc. Magazine as one of “17 Inspiring Women to Watch in 2017” and one of Becker Hospital Review’s “110 Women in Medtech to Know in 2017”.

Dr. Jeff White

Dr. White is a biomedical operations executive with over 15 years’ broad experience in bringing various medical device and therapeutic agents (50+) to market as well as capable general management experience within startups, transitions and turnarounds. Skilled in accounting, fiscal budgets and responsibility, revenue projections, contract negotiations, cost containment, managing change and interfacing with Boards. Focused on integrity, confidentiality, preservation of intellectual property, corporate accountability and team building.   At GCMI, he is responsible for providing corporate administration and general management including; research and training infrastructure services, quality assurance, regulatory compliance, and financial performance. Prior to joining T3 Labs, as a Senior Director he was the principal in establishing LyChron’ s Midwest AAALAC accredited contract research facility dedicated to GLP compliant research within the Veterans Administration in Minneapolis, MN.  As the company’s Chief Veterinarian for more than 7 years, he developed a wide-ranging knowledge base of research techniques for medical devices and therapies in most therapeutic areas.   His technical experience includes complex anesthetic cases, techniques in interventional radiology, various transcutaneous imaging modalities such as ultrasound and fluoroscopy as well as surgical expertise in multiple species. He holds a Doctor of Veterinary Medicine degree from Kansas State University College of Veterinary Medicine and a Bachelor of Arts in Biology from the University of Kansas.

Andrew Stevenson

Executive Director- Business Strategy
Andrew joined GCMI+T3 Labs in 2009.  He has led the site transfer and operational start-up of T3 Labs in a new $20 million world-class facility, re-focused the organization on quality-first service model, built sustainable relationships with Fortune 500 medical device manufacturers, academic and healthcare institutions, and startups alike, established a team of highly-qualified independent consultant-Program Leaders that serve over 150 customers annually, and expanded GCMI and T3 Labs’ service offerings to 13 therapeutic and service-oriented programs. In addition to leading deal-flow and account management for GCMI+T3 Labs services, GCMI recently launched a MedTech Accelerator for which he is accountable.  He is also involved in local and state economic development initiatives for life sciences and healthcare.Prior to moving to GCMI and T3 Labs, he led corporate development raising over $330 million, built and directed three project management offices, support dozens of global development and product launch programs, provided independent consulting services, and conducted laboratory research for several companies.  These companies include Abbott Laboratories/Solvay Pharmaceuticals, Bristol-Myers Squibb/DuPont/Merck, an GA Tech ATDC start-up, and the University of Pennsylvania.  He holds an M.B.A in International Business from the Alfred Lerner College of Business and Economics, University of Delaware and a B.S. in Chemistry from Davidson College.